Navigation Links
Questcor Reports Third Quarter Financial Results
Date:10/29/2013

6140,339556,048348,760Cost of sales (exclusive of amortization of purchased technology and IPR&D asset)20,0347,49953,44419,399Gross profit216,312132,840502,604329,361Operating expenses:Selling and marketing40,71031,763114,07281,087General and administrative15,4288,33341,10322,422Research and development17,0947,99740,12722,147Depreciation and amortization9953393,079951Impairment of purchased technology—987719987Total operating expenses74,22749,419199,100127,594Income from operations142,08583,421303,504201,767Interest and other (expense) income, net(1,976)102(2,298)536Foreign currency transaction loss——(488)—Income before income taxes140,10983,523300,718202,303Income tax expense45,66827,83698,09266,568Net income$

94,441$

55,687$

202,626$

135,735Change in unrealized gains or losses on available-for-sale securities, net of related tax effects and changes in foreign currency translation adjustments.93213(1,742)90Comprehensive income$

95,373$

55,700$

200,884$

135,825Net income per share:Basic$

1.60$

0.95$

3.47$

2.23Diluted$

1.52$

0.91$

3.32$

2.12Shares used in computing net income per share:Basic58,89058,65358,35060,992Diluted62,08461,41761,11963,914Dividends declared per share of common stock$

—$

0.20$

0.50$

0.20 Reconciliation of Non-GAAP Adjusted Financial DisclosureThree Months EndedNine Months EndedSeptember 30,September 30,2013201220132012Adjusted net income

$104,368

$59,427

$233,328

$143,943Share-based compensation expense (1)

(5,269)

(2,855)

(13,807)

(6,908)Depreciation and amortization expense (2)

(3,127)

(226)

(6,253)

(638)Interest expense associated with contingent consideration (3)

(188)

0

(572)

0Interes
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
2. Questcor to Report Second Quarter Results on July 24, 2012
3. Questcor Reports Second Quarter Financial Results
4. Questcor Pharmaceuticals to Present at Investor Conferences in September
5. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
6. Questcor Comments on Insurance Policy Bulletin
7. Questcor to Conduct Conference Call to Discuss Reimbursement Process
8. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
9. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
10. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
11. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... PALO ALTO, Calif., March 8, 2011 Jazz Pharmaceuticals, Inc. ... will be providing a business update at two upcoming investor ... financial officer, will provide an update at the ROTH 23rd ... Monday, March 14, 2011 at 4:30 p.m. Pacific Time ...
... Warner Chilcott plc (Nasdaq: WCRX ) ... its ordinary shares by certain selling shareholders. The selling ... Morgan Partners (advised by CCMP Capital) and Thomas H. ... management. The offering is being conducted as a public ...
Cached Medicine Technology:Warner Chilcott Announces Secondary Equity Offering 2Warner Chilcott Announces Secondary Equity Offering 3Warner Chilcott Announces Secondary Equity Offering 4
(Date:4/17/2014)... The presence of chronic inflammation in benign prostate ... cancer, and this association was found even in ... to a study published in Cancer Epidemiology, ... American Association for Cancer Research. , An analysis ... of the placebo arm of the Prostate Cancer ...
(Date:4/17/2014)... specifically associated with the risk of a difficult-to-diagnose ... of all breast cancer cases. , The largest ... invasive lobular carcinoma, gives researchers important clues to ... breast cancer, which can be missed through screening. ... journal PloS Genetics , was co-led by ...
(Date:4/17/2014)... popular vaccine brands for children may not be the ... cost factors when choosing vaccines, driving the market toward ... a new study by University of Illinois researchers. , ... by numerous factors," says Sheldon H. Jacobson, a co-author ... and of mathematics at the U. of I. "In ...
(Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study recalculates costs of combination vaccines 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2
... ... implicate the purchaser in any lawsuit or cause such purchasers to be a party ... ... highly respected developer and manufacturer of proprietary skin care formulations, who also is the ...
... ... latest version of its revolutionary cost-cutting software. Newly developed upgrades to iCodeRx, iDocs, and ... processes, while providing the highest security possible to patient information. , ... Virginia Beach, VA (PRWEB) - DOMA ...
... ... a new agreement with B. E. Smith for Executive Leadership Solutions. , ... Lenexa, KS (Vocus) September 24, ... agreement with B. E. Smith for Executive Leadership Solutions., , ,Effective immediately, through August ...
... trials, advanced cancers shrunk rapidly, researchers say , THURSDAY, ... advanced melanoma promotes rapid shrinking of tumors, according to ... includes patients with the cancer-causing mutation of the BRAF ... melanomas and 5 percent of colorectal cancers. , The ...
... say , THURSDAY, Sept. 24 (HealthDay News) -- Surgery ... carpal tunnel syndrome who don,t have severe nerve damage ... 44 patients who had surgery and 52 patients who ... A year after treatment, the patients, hand function was ...
... drugs increase the possibility of septal malformation, researchers find ... who take certain antidepressants during the first three months ... giving birth to babies with heart defects. , Septal ... right side of the heart from the left -- ...
Cached Medicine News:Health News:Purchase PHYTO-C Skincare Will Not Implicate in the Lawsuit 2Health News:DOMA Transforms Healthcare IT with Increased Security While Reducing Cost -- iCodeRx/iDocs/iCharts 6.0 Debuts at AHIMA National Convention 2Health News:DOMA Transforms Healthcare IT with Increased Security While Reducing Cost -- iCodeRx/iDocs/iCharts 6.0 Debuts at AHIMA National Convention 3Health News:Members to Benefit from New Agreement between Amerinet and B. E. Smith 2Health News:New Treatment May Beat Melanoma 2Health News:New Treatment May Beat Melanoma 3Health News:Surgery Best for Carpal Tunnel Syndrome 2Health News:Surgery Best for Carpal Tunnel Syndrome 3Health News:Antidepressants Linked to Heart Defects in Newborns 2Health News:Antidepressants Linked to Heart Defects in Newborns 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: